Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study - Scorecard - MDSpire
Advertisement
Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study
Clinical Scorecard: Assessing the Impact of Plasma Cell-Free DNA Methylation Monitoring on Predicting Pathological Outcomes in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: Insights from a Prospective Phase II Study
At a Glance
Category
Detail
Condition
Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms
Utilization of cfDNA methylation patterns and chromosomal alterations as predictive biomarkers for treatment response.
Target Population
Patients aged over 18 with clinical stage IIB to IIIB NSCLC.
Care Setting
Multidisciplinary clinical setting, specifically at Peking University Cancer Hospital & Institute.
Key Highlights
Neoadjuvant toripalimab plus chemotherapy shows promise in treating resectable NSCLC.
cfDNA methylation features may enhance prediction of pathological response.
Integrated models combining cfDNA features and immune parameters are being developed.
Guideline-Based Recommendations
Diagnosis
Utilize RECIST v.1.1 for measurable target lesions.
Incorporate cfDNA methylation profiling for enhanced diagnostic accuracy.
Management
Administer neoadjuvant toripalimab with chemotherapy for eligible patients.
Conduct multidisciplinary evaluations to determine surgical feasibility post-treatment.
Monitoring & Follow-up
Perform radiographical re-evaluation after two cycles of treatment.
Assess cfDNA features before, during, and after therapy.
Risks
Monitor for potential recurrence rates post-surgery (30-60%).
Consider limitations of classical biomarkers in predicting treatment response.
Patient & Prescribing Data
100 patients enrolled with stage IIB to IIIB NSCLC.
Patients received toripalimab, cis-platinum, and pemetrexed or albumin-bound paclitaxel based on tumor subtype.
Clinical Best Practices
Incorporate liquid biopsy techniques for early detection and treatment response prediction.
Utilize integrated models for personalized treatment approaches.
